Trial Outcomes & Findings for A Study of Evacetrapib in High-Risk Vascular Disease (NCT NCT01687998)
NCT ID: NCT01687998
Last Updated: 2019-10-08
Results Overview
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Recruitment status
TERMINATED
Study phase
PHASE3
Target enrollment
12092 participants
Primary outcome timeframe
Baseline to Study Completion (Up to 4 years)
Results posted on
2019-10-08
Participant Flow
Non-Completers: Participants "Known to be Alive at Study End" is a subset of those who did not withdraw consent and later found to be alive from public sources. "Lost to follow-up" is a subset of those who did not withdraw consent for whom study end vital status could not be ascertained.
Participant milestones
| Measure |
Evacetrapib
Evacetrapib 130 milligram (mg) tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
|
Placebo
Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
|
|---|---|---|
|
Overall Study
STARTED
|
6038
|
6054
|
|
Overall Study
Received at Least One Dose of Study Drug
|
6036
|
6052
|
|
Overall Study
COMPLETED
|
5926
|
5934
|
|
Overall Study
NOT COMPLETED
|
112
|
120
|
Reasons for withdrawal
| Measure |
Evacetrapib
Evacetrapib 130 milligram (mg) tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
|
Placebo
Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
49
|
51
|
|
Overall Study
Known to be Alive at Study End
|
54
|
62
|
|
Overall Study
Lost to Follow-up
|
9
|
7
|
Baseline Characteristics
A Study of Evacetrapib in High-Risk Vascular Disease
Baseline characteristics by cohort
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Total
n=12092 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
64.791 years
STANDARD_DEVIATION 9.3849 • n=99 Participants
|
64.994 years
STANDARD_DEVIATION 9.4591 • n=107 Participants
|
64.892 years
STANDARD_DEVIATION 9.4223 • n=206 Participants
|
|
Sex: Female, Male
Female
|
1390 Participants
n=99 Participants
|
1394 Participants
n=107 Participants
|
2784 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
4648 Participants
n=99 Participants
|
4660 Participants
n=107 Participants
|
9308 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
500 Participants
n=99 Participants
|
522 Participants
n=107 Participants
|
1022 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5394 Participants
n=99 Participants
|
5386 Participants
n=107 Participants
|
10780 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
144 Participants
n=99 Participants
|
146 Participants
n=107 Participants
|
290 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
243 Participants
n=99 Participants
|
226 Participants
n=107 Participants
|
469 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
650 Participants
n=99 Participants
|
640 Participants
n=107 Participants
|
1290 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
6 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
11 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
141 Participants
n=99 Participants
|
153 Participants
n=107 Participants
|
294 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
4933 Participants
n=99 Participants
|
4971 Participants
n=107 Participants
|
9904 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
35 Participants
n=99 Participants
|
26 Participants
n=107 Participants
|
61 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
30 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
63 Participants
n=206 Participants
|
|
Region of Enrollment
Russia
|
85 Participants
n=99 Participants
|
82 Participants
n=107 Participants
|
167 Participants
n=206 Participants
|
|
Region of Enrollment
Hong Kong
|
24 Participants
n=99 Participants
|
28 Participants
n=107 Participants
|
52 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
2235 Participants
n=99 Participants
|
2240 Participants
n=107 Participants
|
4475 Participants
n=206 Participants
|
|
Region of Enrollment
Netherlands
|
171 Participants
n=99 Participants
|
169 Participants
n=107 Participants
|
340 Participants
n=206 Participants
|
|
Region of Enrollment
Austria
|
34 Participants
n=99 Participants
|
34 Participants
n=107 Participants
|
68 Participants
n=206 Participants
|
|
Region of Enrollment
Sweden
|
33 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
66 Participants
n=206 Participants
|
|
Region of Enrollment
China
|
224 Participants
n=99 Participants
|
221 Participants
n=107 Participants
|
445 Participants
n=206 Participants
|
|
Region of Enrollment
South Korea
|
87 Participants
n=99 Participants
|
94 Participants
n=107 Participants
|
181 Participants
n=206 Participants
|
|
Region of Enrollment
Poland
|
243 Participants
n=99 Participants
|
240 Participants
n=107 Participants
|
483 Participants
n=206 Participants
|
|
Region of Enrollment
Brazil
|
54 Participants
n=99 Participants
|
56 Participants
n=107 Participants
|
110 Participants
n=206 Participants
|
|
Region of Enrollment
Slovakia
|
116 Participants
n=99 Participants
|
117 Participants
n=107 Participants
|
233 Participants
n=206 Participants
|
|
Region of Enrollment
France
|
45 Participants
n=99 Participants
|
52 Participants
n=107 Participants
|
97 Participants
n=206 Participants
|
|
Region of Enrollment
Bulgaria
|
113 Participants
n=99 Participants
|
118 Participants
n=107 Participants
|
231 Participants
n=206 Participants
|
|
Region of Enrollment
Lithuania
|
13 Participants
n=99 Participants
|
15 Participants
n=107 Participants
|
28 Participants
n=206 Participants
|
|
Region of Enrollment
Argentina
|
89 Participants
n=99 Participants
|
91 Participants
n=107 Participants
|
180 Participants
n=206 Participants
|
|
Region of Enrollment
Romania
|
64 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
130 Participants
n=206 Participants
|
|
Region of Enrollment
Hungary
|
118 Participants
n=99 Participants
|
115 Participants
n=107 Participants
|
233 Participants
n=206 Participants
|
|
Region of Enrollment
Japan
|
205 Participants
n=99 Participants
|
202 Participants
n=107 Participants
|
407 Participants
n=206 Participants
|
|
Region of Enrollment
Ukraine
|
67 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
133 Participants
n=206 Participants
|
|
Region of Enrollment
United Kingdom
|
58 Participants
n=99 Participants
|
58 Participants
n=107 Participants
|
116 Participants
n=206 Participants
|
|
Region of Enrollment
Switzerland
|
15 Participants
n=99 Participants
|
14 Participants
n=107 Participants
|
29 Participants
n=206 Participants
|
|
Region of Enrollment
Spain
|
65 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
131 Participants
n=206 Participants
|
|
Region of Enrollment
New Zealand
|
63 Participants
n=99 Participants
|
64 Participants
n=107 Participants
|
127 Participants
n=206 Participants
|
|
Region of Enrollment
Canada
|
626 Participants
n=99 Participants
|
619 Participants
n=107 Participants
|
1245 Participants
n=206 Participants
|
|
Region of Enrollment
Czechia
|
187 Participants
n=99 Participants
|
185 Participants
n=107 Participants
|
372 Participants
n=206 Participants
|
|
Region of Enrollment
Turkey
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Region of Enrollment
Belgium
|
42 Participants
n=99 Participants
|
42 Participants
n=107 Participants
|
84 Participants
n=206 Participants
|
|
Region of Enrollment
Taiwan
|
52 Participants
n=99 Participants
|
53 Participants
n=107 Participants
|
105 Participants
n=206 Participants
|
|
Region of Enrollment
Denmark
|
95 Participants
n=99 Participants
|
100 Participants
n=107 Participants
|
195 Participants
n=206 Participants
|
|
Region of Enrollment
Italy
|
43 Participants
n=99 Participants
|
40 Participants
n=107 Participants
|
83 Participants
n=206 Participants
|
|
Region of Enrollment
Mexico
|
235 Participants
n=99 Participants
|
231 Participants
n=107 Participants
|
466 Participants
n=206 Participants
|
|
Region of Enrollment
South Africa
|
77 Participants
n=99 Participants
|
76 Participants
n=107 Participants
|
153 Participants
n=206 Participants
|
|
Region of Enrollment
Israel
|
72 Participants
n=99 Participants
|
74 Participants
n=107 Participants
|
146 Participants
n=206 Participants
|
|
Region of Enrollment
Australia
|
159 Participants
n=99 Participants
|
160 Participants
n=107 Participants
|
319 Participants
n=206 Participants
|
|
Region of Enrollment
Germany
|
198 Participants
n=99 Participants
|
202 Participants
n=107 Participants
|
400 Participants
n=206 Participants
|
|
Region of Enrollment
Estonia
|
30 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
59 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline to Study Completion (Up to 4 years)Population: All randomized participants.
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Number of Participants With Composite Primary Endpoint of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Coronary Revascularization, or Hospitalization for Unstable Angina (UA)
|
779 Participants
|
776 Participants
|
SECONDARY outcome
Timeframe: Baseline, 3 MonthsPopulation: All randomized participants with evaluable LDL-C and HDL-C levels.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels
LDL-C
|
-31.12 percent
Standard Deviation 27.583
|
5.99 percent
Standard Deviation 29.007
|
|
Mean Percent Change From Baseline to 3 Months in Low-Density (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) Levels
HDL-C
|
133.18 percent
Standard Deviation 57.204
|
1.63 percent
Standard Deviation 17.455
|
SECONDARY outcome
Timeframe: Baseline through End of Study (Up to 4 years)Population: All randomized participants.
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Number of Participants With Composite Endpoint of All-Cause Mortality, MI, Stroke, Coronary Revascularization, or Hospitalization for UA
|
857 Participants
|
867 Participants
|
SECONDARY outcome
Timeframe: Baseline through End of Study (Up to 4 years)Population: All randomized participants.
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Number of Participants With Composite Endpoint of CV Death, MI, or Coronary Revascularization
|
690 Participants
|
691 Participants
|
SECONDARY outcome
Timeframe: Baseline through End of Study (Up to 4 years)Population: All randomized participants.
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Number of Participants With Composite Endpoint of CV Death, MI, Stroke, or Hospitalization for UA
|
571 Participants
|
570 Participants
|
SECONDARY outcome
Timeframe: Baseline through End of Study (Up to 4 years)Population: All randomized participants.
For component endpoints, the number of participants includes those experiencing fatal events and account for all occurrences regardless of whether or not another component event occurred previously.
Outcome measures
| Measure |
Evacetrapib
n=6038 Participants
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6054 Participants
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Number of Participants With Triple Composite Endpoint of CV Death, MI, or Stroke
|
437 Participants
|
453 Participants
|
Adverse Events
Evacetrapib
Serious events: 2306 serious events
Other events: 2659 other events
Deaths: 0 deaths
Placebo
Serious events: 2341 serious events
Other events: 2529 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Evacetrapib
n=6036 participants at risk
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6052 participants at risk
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Cardiac disorders
Acute coronary syndrome
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Acute myocardial infarction
|
2.4%
146/6036 • Number of events 168
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
2.3%
137/6052 • Number of events 149
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular hypokinesia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular tachyarrhythmia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.27%
16/6036 • Number of events 21
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.40%
24/6052 • Number of events 24
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Wolff-parkinson-white syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebellar ischaemia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebellar syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebral arteriosclerosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebral artery occlusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebral infarction
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebral ischaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebrovascular accident
|
1.0%
61/6036 • Number of events 63
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.0%
62/6052 • Number of events 65
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Rectocele
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.50%
30/6036 • Number of events 31
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.63%
38/6052 • Number of events 46
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Aplastic anaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Coagulopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Cytopenia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Disseminated intravascular coagulation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.05%
3/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Haemorrhagic anaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Heparin-induced thrombocytopenia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Immune thrombocytopenic purpura
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Iron deficiency anaemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Lymphadenopathy mediastinal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Microcytic anaemia
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Normochromic normocytic anaemia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Pernicious anaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Splenic infarction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Blood and lymphatic system disorders
Spontaneous haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Adams-stokes syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Angina pectoris
|
1.7%
102/6036 • Number of events 113
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.6%
98/6052 • Number of events 103
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Angina unstable
|
4.9%
298/6036 • Number of events 389
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
4.8%
289/6052 • Number of events 363
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Aortic valve disease
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Aortic valve incompetence
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Aortic valve sclerosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Arrhythmia
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Arteriospasm coronary
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrial fibrillation
|
1.4%
86/6036 • Number of events 109
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.3%
78/6052 • Number of events 94
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrial flutter
|
0.41%
25/6036 • Number of events 27
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrial tachycardia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrial thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrioventricular block
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Atrioventricular block second degree
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Bradyarrhythmia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Bradycardia
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.18%
11/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac arrest
|
0.28%
17/6036 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.50%
30/6052 • Number of events 32
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac discomfort
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac failure
|
1.1%
67/6036 • Number of events 79
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.0%
63/6052 • Number of events 78
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac failure acute
|
0.18%
11/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac failure chronic
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac failure congestive
|
1.6%
95/6036 • Number of events 134
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.7%
103/6052 • Number of events 138
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiac tamponade
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiogenic shock
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiomyopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiopulmonary failure
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiorenal syndrome
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Cardiovascular insufficiency
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Chronotropic incompetence
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Conduction disorder
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Congestive cardiomyopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Coronary artery disease
|
0.61%
37/6036 • Number of events 40
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.73%
44/6052 • Number of events 45
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Coronary artery dissection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Coronary artery occlusion
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Diastolic dysfunction
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Dressler's syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Extrasystoles
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Hypertensive heart disease
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Intracardiac thrombus
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ischaemic cardiomyopathy
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Left ventricular dysfunction
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Left ventricular failure
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Microvascular coronary artery disease
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.05%
3/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Mitral valve stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Myocardial infarction
|
1.4%
82/6036 • Number of events 88
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.7%
100/6052 • Number of events 107
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.25%
15/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Myocardial rupture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Nodal rhythm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Palpitations
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Pericardial effusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Pericardial haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Pericarditis
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Postinfarction angina
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Prinzmetal angina
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Right ventricular failure
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Sinus arrest
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Sinus node dysfunction
|
0.20%
12/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Sinus tachycardia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Stress cardiomyopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Systolic dysfunction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Tachyarrhythmia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Tachycardia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Cardiac disorders
Ventricle rupture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Arteriovenous malformation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Atrial septal defect
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Dermoid cyst
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Hydrocele
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.04%
2/4658 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Hypertrophic cardiomyopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Leukodystrophy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Congenital, familial and genetic disorders
Phimosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Conductive deafness
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Deafness neurosensory
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Ear pain
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Eustachian tube dysfunction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Meniere's disease
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Otosclerosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Vertigo
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.25%
15/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Ear and labyrinth disorders
Vertigo positional
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Endocrine disorders
Goitre
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Endocrine disorders
Hyperparathyroidism
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Endocrine disorders
Hyperparathyroidism primary
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Age-related macular degeneration
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Cataract
|
0.25%
15/6036 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Cataract nuclear
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Conjunctival haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Diabetic retinopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Diplopia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Ectropion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Entropion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Eye haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Eye pain
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Eyelid ptosis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Glaucoma
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Idiopathic orbital inflammation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Iridocyclitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Iritis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Keratitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Keratopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Lens dislocation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Macular fibrosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Open angle glaucoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Optic atrophy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Optic ischaemic neuropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Optic neuropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Retinal artery occlusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Retinal detachment
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Retinal haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Retinopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Visual acuity reduced
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Visual impairment
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Eye disorders
Vitreous haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal compartment syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal mass
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.30%
18/6036 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal strangulated hernia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal wall cyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Abdominal wall haematoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Alcoholic pancreatitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Anal haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Chronic gastritis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Coeliac artery stenosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Colitis
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Colitis ischaemic
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Colitis microscopic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Colitis ulcerative
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Colonic fistula
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Constipation
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.10%
6/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Dieulafoy's vascular malformation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Diverticular perforation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Diverticulum
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Diverticulum intestinal haemorrhagic
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Duodenal stenosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Duodenal ulcer perforation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Duodenitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Enteritis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Enterovesical fistula
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Erosive oesophagitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Faecal incontinence
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Faecaloma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Femoral hernia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Food poisoning
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric cyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric polyps
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastric ulcer perforation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastritis
|
0.17%
10/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastritis alcoholic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastritis erosive
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastritis haemorrhagic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal angiodysplasia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal angiodysplasia haemorrhagic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal disorder
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.53%
32/6036 • Number of events 32
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.43%
26/6052 • Number of events 32
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal inflammation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrointestinal ulcer haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.22%
13/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.18%
11/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Gingival bleeding
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Glossitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Haematemesis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Haematochezia
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Haemorrhoidal haemorrhage
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Heyde's syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Hiatus hernia
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Ileus
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.25%
15/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.21%
13/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal infarction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intestinal prolapse
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intra-abdominal haematoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Intra-abdominal haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Jejunal perforation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Large intestinal haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Large intestinal stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Large intestine perforation
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Large intestine polyp
|
0.10%
6/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.18%
11/6052 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Localised intraabdominal fluid collection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Mallory-weiss syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Melaena
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Mesenteric vascular insufficiency
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Mouth haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Nausea
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Odynophagia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oedematous pancreatitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophageal achalasia
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophageal oedema
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophageal spasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophageal stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatic mass
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatic pseudocyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.20%
12/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.17%
10/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatitis chronic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatitis haemorrhagic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pancreatitis necrotising
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Peptic ulcer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Peptic ulcer haemorrhage
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Peritoneal adhesions
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Pneumoperitoneum
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Rectal polyp
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Rectal ulcer haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Retroperitoneal effusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Retroperitoneal haematoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Retroperitoneal haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Salivary gland mass
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.18%
11/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Small intestinal perforation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Subileus
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Swollen tongue
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Tongue haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Tongue oedema
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Umbilical hernia
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
|
0.18%
11/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Volvulus
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Gastrointestinal disorders
Vomiting
|
0.15%
9/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Adverse drug reaction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Asthenia
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Cardiac death
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Chest discomfort
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.20%
12/6052 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Chest pain
|
0.61%
37/6036 • Number of events 38
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.56%
34/6052 • Number of events 42
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Hepatic enzyme increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Death
|
0.33%
20/6036 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device breakage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device dislocation
|
0.07%
4/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device end of service
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device failure
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device inappropriate shock delivery
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device malfunction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device material issue
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Device occlusion
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Drowning
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Drug withdrawal syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Exercise tolerance decreased
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Gait disturbance
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
General physical health deterioration
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Generalised oedema
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Granuloma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
International normalised ratio decreased
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Hyperthermia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Hypertrophy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Hypothermia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Impaired healing
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Implant site haematoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Incarcerated hernia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Ischaemic ulcer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Lead dislodgement
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Multi-organ failure
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Necrobiosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Necrosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Non-cardiac chest pain
|
1.8%
107/6036 • Number of events 123
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.8%
108/6052 • Number of events 118
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Oedema
|
0.02%
1/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Oedema peripheral
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Pain
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Pelvic mass
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Peripheral swelling
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Precancerous mucosal lesion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Pyrexia
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Stent-graft endoleak
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Sudden cardiac death
|
0.27%
16/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.25%
15/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Sudden death
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Systemic inflammatory response syndrome
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Thrombosis in device
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Ulcer haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Vascular stent occlusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Vascular stent restenosis
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Vascular stent stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Vascular stent thrombosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
General disorders
Vessel puncture site haematoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Autoimmune hepatitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Bile duct obstruction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Biliary colic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Biliary tract disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholangitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholangitis acute
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.31%
19/6036 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.20%
12/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.25%
15/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholecystitis chronic
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.38%
23/6036 • Number of events 23
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.36%
22/6052 • Number of events 23
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Gallbladder disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hepatic cirrhosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hepatic lesion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hepatic steatosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hepatitis alcoholic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Hydrocholecystis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Ischaemic hepatitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Jaundice
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Jaundice cholestatic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Jaundice extrahepatic obstructive
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Liver disorder
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Liver injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Immune system disorders
Anaphylactic reaction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Immune system disorders
Anaphylactic shock
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Immune system disorders
Drug hypersensitivity
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abdominal abscess
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abdominal infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abdominal sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abdominal wall abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abdominal wall infection
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abscess limb
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abscess neck
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abscess of salivary gland
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Abscess oral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Acute sinusitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Anal abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Appendicitis
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Appendicitis perforated
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Arteriosclerotic gangrene
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Arteritis infective
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Arthritis bacterial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Atypical pneumonia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bacteraemia
|
0.10%
6/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bacterial infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bacterial sepsis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Biliary sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Biliary tract infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Breast cellulitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bronchitis
|
0.41%
25/6036 • Number of events 25
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.30%
18/6052 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bronchitis viral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bursitis infective
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Cellulitis
|
0.68%
41/6036 • Number of events 48
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.69%
42/6052 • Number of events 45
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Cellulitis staphylococcal
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Cholangitis infective
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Cholecystitis infective
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Chronic sinusitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Clostridium difficile colitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Clostridium difficile infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Clostridium difficile sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Colonic abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Cystitis
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Device related infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Diabetic foot infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Diabetic gangrene
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Diverticulitis
|
0.22%
13/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Endocarditis
|
0.03%
2/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Endocarditis bacterial
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Endocarditis enterococcal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Endophthalmitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Enterobacter infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Enterococcal bacteraemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Enterococcal infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Enterococcal sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Epididymitis
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Erysipelas
|
0.10%
6/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Escherichia bacteraemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Escherichia pyelonephritis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Escherichia sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Escherichia urinary tract infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Extradural abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Febrile infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gallbladder abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gallbladder empyema
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gangrene
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.18%
11/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gastritis viral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gastroenteritis
|
0.27%
16/6036 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gastroenteritis norovirus
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Gastroenteritis viral
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Giardiasis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Graft infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Groin abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
H1n1 influenza
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Haematoma infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Hepatitis c
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Hepatitis viral
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Herpes zoster
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Implant site cellulitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Implant site infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Incision site infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infected bite
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infected fistula
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infected seroma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infected skin ulcer
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infectious colitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infectious pleural effusion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Influenza
|
0.18%
11/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infusion site cellulitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Infusion site infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Intervertebral discitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Keratitis bacterial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Klebsiella sepsis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Liver abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Localised infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Lower respiratory tract infection
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Lung abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Lung infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Mastoiditis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Mediastinitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Myelitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Nail bed infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Necrotising fasciitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Oesophageal candidiasis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Orbital infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Osteomyelitis
|
0.22%
13/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Osteomyelitis acute
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Osteomyelitis bacterial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Osteomyelitis chronic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Parainfluenzae virus infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Parotitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Parvovirus infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pelvic abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Penile abscess
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Perihepatic abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Periodontitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Perirectal abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Peritonitis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Peritonitis bacterial
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Peritonsillar abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pilonidal cyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia
|
1.9%
115/6036 • Number of events 128
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.9%
112/6052 • Number of events 122
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia bacterial
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia chlamydial
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia fungal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia influenzal
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia legionella
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia parainfluenzae viral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia pneumococcal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia staphylococcal
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia streptococcal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pneumonia viral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Post procedural cellulitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Post procedural infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Post procedural sepsis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Postoperative abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Postoperative wound infection
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pulmonary sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pulmonary tuberculosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pyelonephritis
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pyelonephritis acute
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Pyelonephritis chronic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Respiratory tract infection
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Respiratory tract infection viral
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Rhinovirus infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Salmonellosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Sepsis
|
0.73%
44/6036 • Number of events 49
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.46%
28/6052 • Number of events 32
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Septic shock
|
0.17%
10/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Sialoadenitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Sinusitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Sinusitis fungal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Skin candida
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Soft tissue infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Spinal cord abscess
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Staphylococcal bacteraemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Staphylococcal infection
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Staphylococcal mediastinitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Staphylococcal sepsis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Streptococcal bacteraemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Streptococcal sepsis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Subcutaneous abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Tooth infection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Tracheobronchitis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Upper respiratory tract infection
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Urinary tract infection
|
0.31%
19/6036 • Number of events 22
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.53%
32/6052 • Number of events 36
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Urinary tract infection bacterial
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Urinary tract infection pseudomonal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Urosepsis
|
0.27%
16/6036 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Vestibular neuronitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Viral infection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Viral labyrinthitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Wound abscess
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Wound infection
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Wound infection bacterial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Wound infection staphylococcal
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Abdominal wound dehiscence
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Accident
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Accidental exposure to product
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Accidental overdose
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Acetabulum fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Alcohol poisoning
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Anaemia postoperative
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Anal injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Anastomotic stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Anastomotic ulcer haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Back injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Brain contusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Cartilage injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Cervical vertebral fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Chemical burn of skin
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Chemical injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Clavicle fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Colon injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Compression fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Concussion
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Contrast media reaction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Coronary artery restenosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Craniocerebral injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Crush injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Cystitis radiation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Extradural haematoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Eye injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Facial bones fracture
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Fall
|
0.65%
39/6036 • Number of events 40
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.83%
50/6052 • Number of events 53
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Fibula fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Foot fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Foreign body
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Fracture
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Gastrointestinal anastomotic complication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Gastrointestinal injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Gastrointestinal stoma complication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Graft thrombosis
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Gun shot wound
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Hand fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Head injury
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Heat illness
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Humerus fracture
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Injury
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Intentional overdose
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Jaw fracture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Joint injury
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Ligament injury
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Ligament sprain
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Limb traumatic amputation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.07%
4/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Lumbar vertebral fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Meniscus injury
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Multiple fractures
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Multiple injuries
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Muscle contusion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Muscle injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Muscle rupture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Nerve root injury lumbar
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Overdose
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Patella fracture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Pelvic fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Peripheral arterial reocclusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Peripheral artery restenosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Periprosthetic fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Poisoning
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post concussion syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post laminectomy syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural bile leak
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural haematoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural haemorrhage
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural myocardial infarction
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Post procedural stroke
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Postoperative fever
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Postoperative respiratory failure
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Postoperative thoracic procedure complication
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Postoperative wound complication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Procedural haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Procedural hypotension
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Pubis fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Pulmonary contusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.25%
15/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.25%
15/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Seroma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Skull fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Soft tissue injury
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Spinal cord injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Spinal cord injury cervical
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Splenic rupture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Sternal fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Stoma site haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Subdural haemorrhage
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Tendon injury
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.13%
8/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Thermal burn
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Tooth fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Traumatic amputation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Traumatic fracture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Traumatic haematoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Traumatic intracranial haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Traumatic liver injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Ulna fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Vascular graft occlusion
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Vascular graft thrombosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Vascular pseudoaneurysm ruptured
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Wound haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Alanine aminotransferase increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Angiogram
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Anticoagulation drug level above therapeutic
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Arteriogram
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Arteriogram coronary
|
0.27%
16/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.28%
17/6052 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Arteriogram renal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Aspartate aminotransferase increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Biopsy brain
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood creatine phosphokinase increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood creatinine increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood glucose decreased
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood glucose increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood osmolarity decreased
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Blood pressure increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Cardiac function test
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Cardiac stress test abnormal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Cardiovascular evaluation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Cardiovascular examination
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Carotid bruit
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Catheterisation cardiac
|
0.17%
10/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Clostridium test positive
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Colonoscopy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Computerised tomogram
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Computerised tomogram thorax
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Diagnostic procedure
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Ejection fraction decreased
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Electrocardiogram abnormal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Electrocardiogram qt prolonged
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Endoscopy gastrointestinal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Gamma-glutamyltransferase increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Heart rate irregular
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
International normalised ratio increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Investigation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Liver function test abnormal
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Myocardial necrosis marker increased
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Oesophagogastroduodenoscopy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Peripheral arteriogram
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Prostatic specific antigen increased
|
0.04%
2/4648 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Transaminases increased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Troponin increased
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Ureteroscopy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Vitamin b12 decreased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Investigations
Weight decreased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.25%
15/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.43%
26/6052 • Number of events 28
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.18%
11/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.33%
20/6052 • Number of events 22
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Diabetes mellitus inadequate control
|
0.13%
8/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Diabetic ketoacidosis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Diabetic metabolic decompensation
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Electrolyte imbalance
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Failure to thrive
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Fluid overload
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Gout
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.22%
13/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hyperosmolar hyperglycaemic state
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.28%
17/6036 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.30%
18/6052 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.10%
6/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Hypovolaemia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Ketoacidosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Lactic acidosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Metabolic acidosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Obesity
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Type 2 diabetes mellitus
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Metabolism and nutrition disorders
Vitamin b12 deficiency
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Ankylosing spondylitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.12%
7/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.28%
17/6052 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.15%
9/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Arthropathy
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.25%
15/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Cervical spinal stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Chondrocalcinosis pyrophosphate
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Compartment syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Costochondritis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's contracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Facet joint syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Fibromyalgia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Foot deformity
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Groin pain
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Haemarthrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc degeneration
|
0.12%
7/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc disorder
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Joint instability
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Kyphosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Ligament laxity
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.22%
13/6036 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.38%
23/6052 • Number of events 24
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Muscle haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.28%
17/6036 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.25%
15/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal discomfort
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Neuropathic arthropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Osteitis
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
1.2%
70/6036 • Number of events 76
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.1%
66/6052 • Number of events 75
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Osteonecrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Pain in jaw
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff syndrome
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Scoliosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Spinal column stenosis
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Spinal osteoarthritis
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Spinal pain
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Spondylolisthesis
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Synovial cyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Synovitis
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Tendon disorder
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Trigger finger
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Vertebral foraminal stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal squamous cell carcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic astrocytoma
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage iv
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.28%
17/6036 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.21%
13/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basosquamous carcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign gastric neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of adrenal gland
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of spinal cord
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign renal neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline mucinous tumour of ovary
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease
|
0.02%
1/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Buschke-lowenstein's tumour
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the gastrointestinal tract
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage 0
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 0
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage 0
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage iii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage iv
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer stage iv
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoplastic melanoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma recurrent
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma stage ii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large b-cell lymphoma stage iii
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial adenocarcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma metastatic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrous histiocytoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenocarcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric adenoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer
|
0.07%
4/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal stromal tumour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal tract adenoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrooesophageal cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gingival cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of liver
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer metastatic
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage iv
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal adenocarcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive breast carcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive lobular breast carcinoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratinising squamous cell carcinoma of nasopharynx
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine benign neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal squamous cell carcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip squamous cell carcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage i
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage ii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage iii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified recurrent
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage ii
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage iii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage iv
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.23%
14/6036 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.21%
13/6052 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage i
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage iii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocytic lymphoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of unknown primary site
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mediastinum neoplasm
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma malignant
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to salivary gland
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic squamous cell carcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxofibrosarcoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal sinus cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm progression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm prostate
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm skin
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma metastatic
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine tumour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-hodgkin's lymphoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage iii
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage iiia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage iv
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma metastatic
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage 0
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral cavity cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal squamous cell carcinoma
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary cystadenoma lymphomatosum
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Phaeochromocytoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Polycythaemia vera
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.56%
26/4648 • Number of events 26
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.60%
28/4658 • Number of events 28
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent
|
0.06%
3/4648 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage ii
|
0.04%
2/4648 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage iv
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenocarcinoma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer metastatic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage 0
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer recurrent
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sinonasal papilloma
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal cord neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.10%
6/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.08%
5/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the oral cavity
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the tongue
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the vulva
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular neoplasm
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure)
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma malignant
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage iv
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm malignant stage unspecified
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsil cancer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsil cancer metastatic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma recurrent
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyoma
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine neoplasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Acute disseminated encephalomyelitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Amyotrophic lateral sclerosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Aphasia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Ataxia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Autonomic nervous system imbalance
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Brain injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Brain mass
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Brain stem stroke
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carotid arteriosclerosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carotid artery disease
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carotid artery occlusion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carotid artery stenosis
|
0.35%
21/6036 • Number of events 21
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.64%
39/6052 • Number of events 42
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carotid sinus syndrome
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Carpal tunnel syndrome
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cerebrovascular insufficiency
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cervical myelopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cervical radiculopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.09%
4/4648 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.04%
2/4658 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Cognitive disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Complex partial seizures
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Complex regional pain syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Dementia
|
0.05%
3/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Dementia alzheimer's type
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Diabetic neuropathy
|
0.10%
6/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Dizziness
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Embolic cerebral infarction
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Embolic stroke
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Encephalopathy
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Epilepsy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Essential tremor
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Guillain-barre syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Haemorrhagic transformation stroke
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Headache
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Hemiparesis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Hypoglycaemic coma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Hypoxic-ischaemic encephalopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Intraventricular haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Ischaemic stroke
|
0.41%
25/6036 • Number of events 25
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.30%
18/6052 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Lacunar infarction
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Loss of consciousness
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Lumbar radiculopathy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Lumbosacral radiculopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Metabolic encephalopathy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Migraine
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Moyamoya disease
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Myasthenia gravis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Myelitis transverse
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Myoclonus
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Nerve compression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Nerve root compression
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Nervous system disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Neuralgia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Neuropathy peripheral
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Normal pressure hydrocephalus
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Parkinson's disease
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Partial seizures
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Peroneal nerve palsy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Post herpetic neuralgia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Postictal paralysis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Presyncope
|
0.13%
8/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Quadriparesis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Quadriplegia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Radicular syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Radiculopathy
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Restless legs syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Sciatica
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Seizure
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Spinal claudication
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Spinal cord compression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Spinal cord infarction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Spinal cord oedema
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Status epilepticus
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Subarachnoid haemorrhage
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Syncope
|
0.76%
46/6036 • Number of events 48
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.86%
52/6052 • Number of events 54
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Thalamus haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Thrombotic stroke
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Toxic encephalopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Transient global amnesia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.61%
37/6036 • Number of events 44
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.64%
39/6052 • Number of events 42
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Tremor
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Trigeminal neuralgia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Uraemic encephalopathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vascular dementia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vascular encephalopathy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vasogenic cerebral oedema
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vertebral artery stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vertebrobasilar insufficiency
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vertigo cns origin
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Viith nerve paralysis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vith nerve paralysis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Vith nerve paresis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Pregnancy, puerperium and perinatal conditions
Pregnancy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Abnormal behaviour
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Acute psychosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Acute stress disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Adjustment disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Adjustment disorder with anxiety
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Adjustment disorder with depressed mood
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Adjustment disorder with mixed disturbance of emotion and conduct
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Aggression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Alcohol abuse
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Alcohol withdrawal syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Alcoholism
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Anxiety
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Anxiety disorder
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Completed suicide
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Confusional state
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Delirium
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Delirium tremens
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Depression
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Depression suicidal
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Generalised anxiety disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Hallucination
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Hypomania
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Major depression
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Mental disorder
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Mental status changes
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.21%
13/6052 • Number of events 15
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Panic attack
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Post-traumatic stress disorder
|
0.02%
1/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Psychogenic seizure
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Psychotic disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Suicidal ideation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Psychiatric disorders
Suicide attempt
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.80%
48/6036 • Number of events 58
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.1%
67/6052 • Number of events 81
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Acute prerenal failure
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Azotaemia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Bladder outlet obstruction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Bladder prolapse
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Calculus ureteric
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Calculus urinary
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Chronic kidney disease
|
0.15%
9/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Cystitis haemorrhagic
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Cystitis ulcerative
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Diabetic nephropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Dysuria
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Glomerulonephritis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Glomerulosclerosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Haematuria
|
0.18%
11/6036 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Hypotonic urinary bladder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.31%
19/6036 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Nephropathy
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Nephrosclerosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Nephrotic syndrome
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Obstructive uropathy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Pelvi-ureteric obstruction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Prerenal failure
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal artery stenosis
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal colic
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal cyst
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal failure
|
0.23%
14/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.18%
11/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal haematoma
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal impairment
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal infarct
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal injury
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal tubular necrosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Renal vein thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Stress urinary incontinence
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Tubulointerstitial nephritis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Ureteral disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urethral haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urethral stenosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urinary bladder haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urinary retention
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.15%
9/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Amastia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.22%
10/4648 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
12/4658 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Cervical polyp
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Cystocele
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Dysmenorrhoea
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Menometrorrhagia
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Ovarian cyst
|
0.14%
2/1388 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Penile necrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Peyronie's disease
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Testicular disorder
|
0.02%
1/4648 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Uterine polyp
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.14%
2/1388 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.14%
2/1394 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
|
0.13%
8/6036 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
0.23%
14/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.33%
20/6052 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Alveolitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Asphyxia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.13%
8/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchiectasis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis chronic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.71%
43/6036 • Number of events 55
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.78%
47/6052 • Number of events 55
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Chylothorax
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.43%
26/6036 • Number of events 29
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.38%
23/6052 • Number of events 23
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Hydrothorax
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Hypercapnia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Idiopathic pulmonary fibrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Lung consolidation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Mediastinal haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal septum deviation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Organising pneumonia
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pickwickian syndrome
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.20%
12/6052 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumomediastinum
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia aspiration
|
0.12%
7/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax spontaneous
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary alveolar haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary arterial hypertension
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary congestion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
0.35%
21/6036 • Number of events 22
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.33%
20/6052 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary hypertension
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary infarction
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.13%
8/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory arrest
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.28%
17/6036 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 17
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnoea syndrome
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Tracheomalacia
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Angioedema
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Decubitus ulcer
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Dermal cyst
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial stenosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Dermatomyositis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Diabetic foot
|
0.17%
10/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Diabetic neuropathic ulcer
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Henoch-schonlein purpura
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Hypersensitivity vasculitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Skin and subcutaneous tissue disorders
Vasculitic rash
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Abdominal hernia repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Adrenalectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Amputation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Analgesic therapy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Aneurysm repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Angioplasty
|
0.20%
12/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.13%
8/6052 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Ankle arthroplasty
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Aortic aneurysm repair
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Aortic bypass
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Aortic valve repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Aortic valve replacement
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Arterial stent insertion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Atherectomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Atrial septal defect repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Autonomic nerve operation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Bladder neck suspension
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Bone operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Bronchial lesion excision
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cancer surgery
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac ablation
|
0.05%
3/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac pacemaker battery replacement
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac pacemaker insertion
|
0.10%
6/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac pacemaker replacement
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac rehabilitation therapy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardiac resynchronisation therapy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cardioversion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Carotid angioplasty
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Carotid endarterectomy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Carotid revascularisation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Carpal tunnel decompression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cataract operation
|
0.05%
3/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Catheter placement
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cholecystectomy
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Colectomy
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Colostomy closure
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Coronary angioplasty
|
0.22%
13/6036 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.35%
21/6052 • Number of events 23
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Coronary arterial stent insertion
|
0.18%
11/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.20%
12/6052 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Coronary artery bypass
|
0.89%
54/6036 • Number of events 54
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.97%
59/6052 • Number of events 59
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Coronary revascularisation
|
1.4%
82/6036 • Number of events 92
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
1.3%
79/6052 • Number of events 89
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Cox-maze procedure
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Debridement
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Diaphragmatic operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Elective surgery
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Endarterectomy
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Endovenous ablation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Explorative laparotomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Exploratory operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Eye operation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Foot amputation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Gastrectomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Gastric bypass
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Gastrointestinal endoscopic therapy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Haematoma evacuation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Heart valve replacement
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Hernia repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
High frequency ablation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.18%
11/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Hip surgery
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Hospitalisation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Hysterectomy
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
1/1394 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Implantable defibrillator insertion
|
0.18%
11/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.21%
13/6052 • Number of events 13
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Implantable defibrillator replacement
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Incisional drainage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Incisional hernia repair
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Inguinal hernia repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.08%
5/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Intervertebral disc operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Intraocular lens implant
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Joint arthroplasty
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Knee arthroplasty
|
0.20%
12/6036 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.20%
12/6052 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Knee operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Leg amputation
|
0.08%
5/6036 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Lens extraction
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Lipoma excision
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Mastectomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Medical device change
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Medical device removal
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Mitral valve replacement
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Nephrectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Open reduction of fracture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Osteosynthesis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Osteotomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Pancreatectomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Pancreaticoduodenectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Penile repair
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Percutaneous coronary intervention
|
3.2%
192/6036 • Number of events 217
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
3.0%
182/6052 • Number of events 214
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral artery angioplasty
|
0.05%
3/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral artery bypass
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral artery stent insertion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral endarterectomy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 6
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral nerve transposition
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Peripheral revascularisation
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Prostate ablation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Prostatectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.04%
2/4658 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Radioactive iodine therapy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Rectal prolapse repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Renal artery angioplasty
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Renal sympathetic nerve ablation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Resection of rectum
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Resuscitation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Retinopexy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Rotator cuff repair
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Shoulder arthroplasty
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Shoulder operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Skin neoplasm excision
|
0.02%
1/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Spinal decompression
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Spinal fusion surgery
|
0.08%
5/6036 • Number of events 5
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Spinal laminectomy
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Spinal operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Stent placement
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Sympathectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Tenotomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Therapeutic embolisation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Therapy cessation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Thrombectomy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Thrombosis prophylaxis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Thyroidectomy
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Toe amputation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Tongue operation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Total adrenalectomy
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Transmyocardial revascularisation
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Transurethral bladder resection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Transurethral prostatectomy
|
0.04%
2/4648 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/4658 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Tricuspid valve repair
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Tumour excision
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Ureteral stent insertion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Ureteral stent removal
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Vaginal prolapse repair
|
0.07%
1/1388 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Valvuloplasty cardiac
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Vascular graft
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Venous stent insertion
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Ventricular assist device insertion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Vitrectomy
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Surgical and medical procedures
Wound drainage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Accelerated hypertension
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aneurysm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic aneurysm
|
0.30%
18/6036 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic aneurysm rupture
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic elongation
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic occlusion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic rupture
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortic stenosis
|
0.30%
18/6036 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.28%
17/6052 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Aortitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial disorder
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial haemorrhage
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial insufficiency
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial occlusive disease
|
0.05%
3/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arterial perforation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Arteriosclerosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Artery dissection
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Axillary vein thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Blood pressure inadequately controlled
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Brachiocephalic artery stenosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Circulatory collapse
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Deep vein thrombosis
|
0.18%
11/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Dry gangrene
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Embolism arterial
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Extremity necrosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Femoral artery aneurysm
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Femoral artery occlusion
|
0.12%
7/6036 • Number of events 8
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.12%
7/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Femoral artery perforation
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Haematoma
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypertension
|
0.35%
21/6036 • Number of events 23
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.30%
18/6052 • Number of events 19
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypertensive crisis
|
0.15%
9/6036 • Number of events 9
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.23%
14/6052 • Number of events 16
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypertensive emergency
|
0.05%
3/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypotension
|
0.18%
11/6036 • Number of events 12
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.28%
17/6052 • Number of events 18
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypovolaemic shock
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Iliac artery occlusion
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.05%
3/6052 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Iliac artery rupture
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Intermittent claudication
|
0.12%
7/6036 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.26%
16/6052 • Number of events 20
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Jugular vein thrombosis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Lymphatic fistula
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Lymphorrhoea
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Malignant hypertension
|
0.07%
4/6036 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Orthostatic hypotension
|
0.18%
11/6036 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.86%
52/6036 • Number of events 66
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.83%
50/6052 • Number of events 66
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral artery aneurysm
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral artery stenosis
|
0.31%
19/6036 • Number of events 21
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 10
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral artery thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.10%
6/6052 • Number of events 7
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral embolism
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral ischaemia
|
0.20%
12/6036 • Number of events 14
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.33%
20/6052 • Number of events 25
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.35%
21/6036 • Number of events 25
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.17%
10/6052 • Number of events 11
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Shock
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Shock haemorrhagic
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Subclavian artery occlusion
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Subclavian artery stenosis
|
0.03%
2/6036 • Number of events 3
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.07%
4/6052 • Number of events 4
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Subclavian artery thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Temporal arteritis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Thrombophlebitis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Thrombophlebitis superficial
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Varicose vein
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.03%
2/6052 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Vascular occlusion
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/6036
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.02%
1/6052 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Vena cava thrombosis
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Venous thrombosis
|
0.03%
2/6036 • Number of events 2
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Venous thrombosis limb
|
0.02%
1/6036 • Number of events 1
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
0.00%
0/6052
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
Other adverse events
| Measure |
Evacetrapib
n=6036 participants at risk
Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
Placebo
n=6052 participants at risk
Placebo, tablet administered orally once daily for up to 4 years. Participants received standard of care for HRVD.
|
|---|---|---|
|
Gastrointestinal disorders
Diarrhoea
|
7.8%
472/6036 • Number of events 568
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
6.8%
414/6052 • Number of events 484
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Bronchitis
|
6.0%
363/6036 • Number of events 456
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
6.2%
375/6052 • Number of events 443
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Nasopharyngitis
|
7.5%
452/6036 • Number of events 603
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
7.7%
465/6052 • Number of events 602
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Infections and infestations
Upper respiratory tract infection
|
5.4%
327/6036 • Number of events 397
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
5.4%
327/6052 • Number of events 410
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
6.2%
375/6036 • Number of events 426
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
6.1%
370/6052 • Number of events 425
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
6.6%
399/6036 • Number of events 442
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
6.3%
379/6052 • Number of events 412
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
5.6%
339/6036 • Number of events 412
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
5.4%
329/6052 • Number of events 388
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Nervous system disorders
Dizziness
|
6.4%
389/6036 • Number of events 435
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
5.8%
352/6052 • Number of events 407
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
5.4%
327/6036 • Number of events 367
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
4.6%
279/6052 • Number of events 304
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
5.1%
305/6036 • Number of events 339
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
5.1%
307/6052 • Number of events 341
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
|
Vascular disorders
Hypertension
|
7.5%
453/6036 • Number of events 508
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
6.7%
403/6052 • Number of events 466
All randomized participants who received at least one dose of study drug. 4 participants were randomized but never took drug and were not in the safety population. 2 females were assigned to evacetrapib and 2 males were assigned to placebo.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60